EP2200550A4 - Formulations topiques de glycopyrrolate - Google Patents

Formulations topiques de glycopyrrolate

Info

Publication number
EP2200550A4
EP2200550A4 EP08839892.0A EP08839892A EP2200550A4 EP 2200550 A4 EP2200550 A4 EP 2200550A4 EP 08839892 A EP08839892 A EP 08839892A EP 2200550 A4 EP2200550 A4 EP 2200550A4
Authority
EP
European Patent Office
Prior art keywords
glycopyrrolate formulations
topical glycopyrrolate
topical
formulations
glycopyrrolate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP08839892.0A
Other languages
German (de)
English (en)
Other versions
EP2200550B1 (fr
EP2200550A1 (fr
Inventor
Michael Johnston
Robert James Houlden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ROSE U, LLC
Original Assignee
Rose U
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40567708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2200550(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rose U filed Critical Rose U
Priority to EP18167442.5A priority Critical patent/EP3415127B1/fr
Publication of EP2200550A1 publication Critical patent/EP2200550A1/fr
Publication of EP2200550A4 publication Critical patent/EP2200550A4/fr
Application granted granted Critical
Publication of EP2200550B1 publication Critical patent/EP2200550B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0208—Tissues; Wipes; Patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
EP08839892.0A 2007-10-18 2008-10-17 Formulations topiques de glycopyrrolate Active EP2200550B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP18167442.5A EP3415127B1 (fr) 2007-10-18 2008-10-17 Formulations topiques de glycopyrrolate et une lingette en contenant

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96088707P 2007-10-18 2007-10-18
PCT/US2008/011907 WO2009051818A1 (fr) 2007-10-18 2008-10-17 Formulations topiques de glycopyrrolate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP18167442.5A Division EP3415127B1 (fr) 2007-10-18 2008-10-17 Formulations topiques de glycopyrrolate et une lingette en contenant

Publications (3)

Publication Number Publication Date
EP2200550A1 EP2200550A1 (fr) 2010-06-30
EP2200550A4 true EP2200550A4 (fr) 2016-01-27
EP2200550B1 EP2200550B1 (fr) 2018-04-18

Family

ID=40567708

Family Applications (2)

Application Number Title Priority Date Filing Date
EP08839892.0A Active EP2200550B1 (fr) 2007-10-18 2008-10-17 Formulations topiques de glycopyrrolate
EP18167442.5A Active EP3415127B1 (fr) 2007-10-18 2008-10-17 Formulations topiques de glycopyrrolate et une lingette en contenant

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP18167442.5A Active EP3415127B1 (fr) 2007-10-18 2008-10-17 Formulations topiques de glycopyrrolate et une lingette en contenant

Country Status (7)

Country Link
US (6) US8618160B2 (fr)
EP (2) EP2200550B1 (fr)
AU (2) AU2008314628B2 (fr)
CA (1) CA2702830C (fr)
ES (1) ES2671874T3 (fr)
MX (1) MX2010004262A (fr)
WO (1) WO2009051818A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100063004A1 (en) * 2006-12-04 2010-03-11 Ranjan Ray Chaudhuri Topical pharmaceutical composition
CA2702830C (fr) 2007-10-18 2017-02-28 Stiefel Research Australia Pty Ltd Formulations topiques de glycopyrrolate
CN102695496B (zh) * 2009-12-23 2014-10-01 奇斯药制品公司 用于copd的气雾剂制剂
AU2010334859A1 (en) 2009-12-23 2012-07-12 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
CA2785317C (fr) 2009-12-23 2018-02-27 Chiesi Farmaceutici S.P.A. Preparation aerosol pour copd (bronchopneumopathie chronique obstructive)
JP6242402B2 (ja) 2013-01-03 2017-12-06 ハイドロス セラピューティクス インターナショナル アクチエボラグ 多汗症の治療
JP6114841B2 (ja) * 2013-02-28 2017-04-12 ダーミラ， インク．Ｄｅｒｍｉｒａ， Ｉｎｃ． グリコピロレート塩
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
TR201808040T4 (tr) * 2013-03-15 2018-06-21 Bodor Laboratories Inc Hiperhidrozun tedavisine yönelik yumuşak antikolinerjik esterler.
EP3027184A1 (fr) * 2013-07-30 2016-06-08 GlaxoSmithKline Intellectual Property Development Limited Compositions topiques pour le traitement d'une sudation excessive et procédé pour les utiliser
US20150259283A1 (en) 2014-03-13 2015-09-17 Brickell Biotech, Inc. Formulation for soft anticholinergic analogs
WO2015138700A1 (fr) 2014-03-13 2015-09-17 Bodor Laboratories, Inc. Utilisation de zwitterions anticholinergiques sélectionnés
US9926270B2 (en) 2014-08-20 2018-03-27 Dermira, Inc. Process for production of glycopyrronium tosylate
JP2017528426A (ja) * 2014-08-27 2017-09-28 ダーミラ， インク．Ｄｅｒｍｉｒａ， Ｉｎｃ． 多汗症を治療する方法
US20220233500A1 (en) * 2014-08-29 2022-07-28 Journey Medical Corporation Glycopyrrolate salts
EA034348B1 (ru) 2014-10-24 2020-01-30 Юнилевер Н.В. Способ и устройство для контроля потоотделения
WO2016062584A1 (fr) 2014-10-24 2016-04-28 Unilever Plc Distributeur pour crème, gel ou composition solide molle
US10227594B2 (en) 2015-03-20 2019-03-12 Conopco, Inc. Antiperspirant composition
EP3325487B1 (fr) 2015-07-21 2021-05-05 Bodor Laboratories, Inc. Préparation pour analogues d'anticholinergiques à potentiel modéré
PT109445B (pt) 2016-06-08 2018-11-06 Hovione Farm Sa Co-cristais farmacêuticos cristalinos de brometo de glicopirrónio com lactose
TWI719046B (zh) 2016-07-21 2021-02-21 美商波德實驗股份有限公司 軟性抗膽鹼類似物之製劑
CA3030772A1 (fr) 2016-08-02 2018-02-08 Dermira, Inc. Procedes de fabrication et procedes d'utilisation de composes glycopyrronium
WO2021053093A1 (fr) 2019-09-20 2021-03-25 Unilever Ip Holdings B.V. Compositions antitranspirantes
WO2021113260A1 (fr) 2019-12-02 2021-06-10 Dermira, Inc. Composés contenant un diester pour le traitement de l'hyperhydrose
WO2022258385A2 (fr) 2021-06-07 2022-12-15 Unilever Ip Holdings B.V. Compositions et méthodes de régulation de la production de sueur

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2018713A (en) * 1978-04-14 1979-10-24 Owens Illinois Inc Composite container
WO1993025186A1 (fr) * 1992-06-16 1993-12-23 Klein Marvin E Composition pour le traitement de la peau
US5403588A (en) * 1993-11-23 1995-04-04 Santa Ana, Jr.; Cesareo T. Disposable body deodorant pad and deodorant preparation therefor
US6211250B1 (en) * 1996-11-22 2001-04-03 Soltec Research Pty Ltd. Percutaneous delivery system
US6433003B1 (en) * 1999-04-23 2002-08-13 Arthur M. Bobrove Method for treating hyperhidrosis in mammals
WO2006069998A2 (fr) * 2004-12-27 2006-07-06 Beiersdorf Ag Le compose glycopyrrolate dans des preparations cosmetiques
US20060165765A1 (en) * 2002-05-03 2006-07-27 Willem Wassenaar Topical glycopyrrolate product

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2118566A (en) 1935-08-29 1938-05-24 Miles Gilbert De Wayne Buffered cosmetic
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3767786A (en) 1961-04-20 1973-10-23 Procter & Gamble Inhibiting perspiration with scopolamine esters
IL22666A (en) 1964-01-06 1968-10-24 Robins Co Inc A H Compositions for inhibiting perspiration containing an 1,1-dialkyl-3-hydroxy-pyrrolidinium ester of an alpha-phenyl-alpha-cycloalkyl-clycolic or acetic acid
US3312709A (en) 1964-06-29 1967-04-04 Procter & Gamble Para-(lower)alkoxybenzoylscopolamine
DE1670048C3 (de) 1966-01-26 1980-09-04 C.H. Boehringer Sohn, 6507 Ingelheim Neue Norscopolaminderivate
US4355020A (en) 1977-11-12 1982-10-19 Bert Kuy Thixotropic aluminum hydroxide chloride and medical and other applications thereof
US4415551A (en) * 1982-01-29 1983-11-15 The Gillette Company Bioerodible deodorant
US4824676A (en) 1984-10-11 1989-04-25 Schering Corporation Physiological means of enhancing transdermal delivery of drugs
US4891227A (en) 1988-02-02 1990-01-02 Richardson-Vicks Inc. Medicated cleansing pads
GB8811408D0 (en) * 1988-05-13 1988-06-15 Unilever Plc Cosmetic composition
US4883792A (en) * 1989-01-17 1989-11-28 Peter Timmins Steroid cream formulation
US5525347A (en) 1995-01-31 1996-06-11 Medical University Of South Carolina Composition and methods for treating performance anxiety
US5648083A (en) * 1995-02-10 1997-07-15 The Procter & Gamble Company Personal care compositions and wipe products containing the compositions
US5919760A (en) 1996-04-12 1999-07-06 Intensive Narcotic Detoxification Centers Of America, Llc Method for treating acute and severe diarrhea
US6214792B1 (en) 1996-04-12 2001-04-10 David Lew Simon Method for treating acute and severe diarrhea
WO1998000133A1 (fr) 1996-07-01 1998-01-08 Sepracor, Inc. Procedes et compositions de traitement de l'incontinence urinaire par (s,s)-glycopyrrolate enrichi par enantiomorphisme
WO1998000016A1 (fr) 1996-07-01 1998-01-08 Sepracor, Inc. Procedes et compositions de traitement de l'incontinence urinaire par (r, r)-glycopyrrolate enrichi par enantiomere
ES2118053B1 (es) 1997-02-27 1999-03-01 Julia Capmany Font M Luisa Producto para la limpieza de la piel y faneras.
US5962505A (en) 1998-08-31 1999-10-05 Bobrove; Arthur M. Method for treating hot flashes in humans
US5976499A (en) 1998-09-04 1999-11-02 Johns Hopkins University Macroscopic sweat test for cystic fibrosis
US6446795B1 (en) 2000-07-31 2002-09-10 The Gillette Company Towelette packaging
ATE324335T1 (de) * 2001-12-22 2006-05-15 Procter & Gamble Verpackung für zusammenpressbare produkte sowie verfahren zur herstellung der verpackung
CA2384922C (fr) 2002-05-03 2008-09-02 Purepharm Inc. Produit topique de glycopyrrolate pour reduire la transpiration
NZ560206A (en) 2005-03-16 2009-09-25 Meda Pharma Gmbh & Co Kg The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
CA2702830C (fr) 2007-10-18 2017-02-28 Stiefel Research Australia Pty Ltd Formulations topiques de glycopyrrolate
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
JP6114841B2 (ja) 2013-02-28 2017-04-12 ダーミラ， インク．Ｄｅｒｍｉｒａ， Ｉｎｃ． グリコピロレート塩
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2018713A (en) * 1978-04-14 1979-10-24 Owens Illinois Inc Composite container
WO1993025186A1 (fr) * 1992-06-16 1993-12-23 Klein Marvin E Composition pour le traitement de la peau
US5403588A (en) * 1993-11-23 1995-04-04 Santa Ana, Jr.; Cesareo T. Disposable body deodorant pad and deodorant preparation therefor
US6211250B1 (en) * 1996-11-22 2001-04-03 Soltec Research Pty Ltd. Percutaneous delivery system
US6433003B1 (en) * 1999-04-23 2002-08-13 Arthur M. Bobrove Method for treating hyperhidrosis in mammals
US20060165765A1 (en) * 2002-05-03 2006-07-27 Willem Wassenaar Topical glycopyrrolate product
WO2006069998A2 (fr) * 2004-12-27 2006-07-06 Beiersdorf Ag Le compose glycopyrrolate dans des preparations cosmetiques

Also Published As

Publication number Publication date
AU2014203072A1 (en) 2014-07-03
WO2009051818A1 (fr) 2009-04-23
MX2010004262A (es) 2010-05-14
US10052267B2 (en) 2018-08-21
EP2200550B1 (fr) 2018-04-18
CA2702830C (fr) 2017-02-28
EP3415127A1 (fr) 2018-12-19
US11071694B2 (en) 2021-07-27
EP3415127B1 (fr) 2023-12-20
US20100276329A1 (en) 2010-11-04
US20210290496A1 (en) 2021-09-23
US20180311116A1 (en) 2018-11-01
ES2671874T3 (es) 2018-06-11
US20230270631A1 (en) 2023-08-31
US20140151255A1 (en) 2014-06-05
CA2702830A1 (fr) 2009-04-23
US8618160B2 (en) 2013-12-31
AU2008314628B2 (en) 2014-03-06
AU2014203072C1 (en) 2019-04-04
AU2008314628A1 (en) 2009-04-23
AU2014203072B2 (en) 2016-05-26
EP2200550A1 (fr) 2010-06-30
US9744105B2 (en) 2017-08-29
US20180008517A1 (en) 2018-01-11

Similar Documents

Publication Publication Date Title
EP2200550A4 (fr) Formulations topiques de glycopyrrolate
GB0709513D0 (en) Topical formulations
ZA201400071B (en) Topical formulations having enhanced bioavailability
GB0711656D0 (en) Formulations
GB0716385D0 (en) Formulations
ZA201002072B (en) Topical composition
ZA200803150B (en) Topical Formulations
GB0712884D0 (en) Formulations
GB0720716D0 (en) Novel formulation
IL206467A0 (en) Formulation
GB0711957D0 (en) Formulations
ZA201003055B (en) Topical composition
GB0809979D0 (en) Formulations
GB0707463D0 (en) Formulation
GB0810232D0 (en) Formulations
EP2124938A4 (fr) Formulation topique
GB0822059D0 (en) Germicidal topical compositions
GB0808479D0 (en) Topical compositions
GB0715723D0 (en) Formulation
EP1895843A4 (fr) Formules topiques de micogel
GB0712972D0 (en) Formulation
GB0808196D0 (en) Topical composition
GB0705179D0 (en) Formulations
ZA200901574B (en) Topical compositions
ZA200806951B (en) Homeopathy-based formulation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100422

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ROSE U

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20160105

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 8/49 20060101ALI20151221BHEP

Ipc: A61K 47/32 20060101ALI20151221BHEP

Ipc: A61K 31/40 20060101ALI20151221BHEP

Ipc: A61K 47/10 20060101ALI20151221BHEP

Ipc: A61K 9/00 20060101ALI20151221BHEP

Ipc: A61K 8/02 20060101ALI20151221BHEP

Ipc: A61Q 15/00 20060101ALI20151221BHEP

Ipc: A61F 13/00 20060101AFI20151221BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20161123

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ROSE U, LLC

INTG Intention to grant announced

Effective date: 20171016

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAR Information related to intention to grant a patent recorded

Free format text: ORIGINAL CODE: EPIDOSNIGR71

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

INTC Intention to grant announced (deleted)
AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

INTG Intention to grant announced

Effective date: 20180312

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 989642

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180515

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602008054929

Country of ref document: DE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2671874

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20180611

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20180418

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180718

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180718

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180719

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 989642

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180418

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180820

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602008054929

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20190121

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20181031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181017

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181017

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181017

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: NEW ADDRESS: ROUTE DU COUTSET 18, 1485 NUVILLY (CH)

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20081017

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180818

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602008054929

Country of ref document: DE

Representative=s name: VENNER SHIPLEY GERMANY LLP, DE

Ref country code: DE

Ref legal event code: R082

Ref document number: 602008054929

Country of ref document: DE

Representative=s name: VENNER SHIPLEY LLP, DE

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230527

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231027

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231102

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20231023

Year of fee payment: 16

Ref country code: FR

Payment date: 20231025

Year of fee payment: 16

Ref country code: DE

Payment date: 20231027

Year of fee payment: 16

Ref country code: CH

Payment date: 20231102

Year of fee payment: 16